Women's Health · LP-107
Tranexamic acid Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-107Women's Health
- Generic identity
- Tranexamic acidTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-107
- Generic ingredient
- Tranexamic acid
- Dosage form
- Tablet
- Proposed strength
- 250 mg; 500 mg
- Proposed pack
- Blister 10 x 10 tablets
- Portfolio category
- Women's Health
About Tranexamic acid
Tranexamic acid is an antifibrinolytic medicine. It helps reduce bleeding by slowing the breakdown of fibrin within blood clots, rather than replacing missing blood cells or treating the cause of every bleeding episode. Oral tablets have uses in selected bleeding conditions under an appropriate diagnosis. The medicine should be evaluated in the context of the source, severity and consequences of bleeding.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Heavy menstrual bleeding is one common context discussed in public medicine information, while other settings require their own specialist guidance. New, severe, unexplained or postmenopausal bleeding needs investigation. A tablet presentation differs from an injectable product used in an acute-care setting. This entry contains educational ingredient information and commercial presentation details; it is not a treatment algorithm, a dosing recommendation or proof of an authorized indication for this candidate.
Important safety considerations
Past or active thrombosis, kidney impairment, visual symptoms and concurrent hormonal therapy may require particular review. Sudden breathlessness, chest pain, a painful swollen limb or new visual disturbance need urgent medical assessment. Gastrointestinal adverse effects can occur. Renal function affects prescribing decisions, and some combinations may increase thrombotic risk. The full local label must be used to assess contraindications and interactions rather than relying on this selected risk summary.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The catalogue lists oral tablets in two strengths. A tablet strength is not equivalent to an injection concentration. Scoring, excipients and suitability for swallowing difficulties or altered administration require confirmation from the specific approved product information.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm the cause and severity of bleeding, kidney function, thrombosis history, concurrent medicines and need for investigation. Use presentation-specific authorized information.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Tranexamic acid
- Dosage form / presentation
- Tablet
- Catalogue strength
- 250 mg; 500 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Portfolio category
- Women's Health
Layer 02
Unresolved product-specific fields
- Exact release/coating/scoring characteristics and formulation-specific administration instructions require controlled product documentation where applicable.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- NHS: tranexamic acidpublic health service medicine information
- NHS: tranexamic acid adverse effectsgovernment or public health guidance
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming the exact ingredient identity, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-107, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-107.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.